Iclusig savings card: as little as $0 a prescription with commercial insurance

How to pay the least

Ask for the cash price

Iclusig

We didn’t find one.

Ask your pharmacy for Iclusig’s cash price, and one or two other pharmacies too.
Iclusig’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Takeda Oncology Patient Assistance Program (Takeda Oncology Here2Assist). To be eligible for the Patient Assistance Program, patients must meet certain financial and insurance coverage criteria. Or call 1-844-817-6468 (Option 2).

See if you qualify

Compare every option

Brand nameIclusig

Authorized genericponatinib

Regular genericponatinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Iclusig?

The original

–

Brand nameThe maker’s card

Takeda Oncology Co-Pay Assistance Program

Savings card from Takeda

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a prescription

Or call 1-844-817-6468.

In the maker’s words

“You could pay as little as $0 per prescription…”

From the maker’s offer on iclusig.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Iclusig itself, from the same company, sold without the brand name, and usually for less. For now Iclusig is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with:

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.

Chronic Myeloid Leukemia (CML)

Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.
Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.
T315I-positive CML (chronic phase, accelerated phase, or blast phase).

Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.

Source: the FDA label for Iclusig (Takeda Pharmaceuticals America, Inc.), August 14, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/iclusig/